1. Home
  2. SATL vs ESPR Comparison

SATL vs ESPR Comparison

Compare SATL & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Satellogic Inc.

SATL

Satellogic Inc.

HOLD

Current Price

$4.61

Market Cap

679.0M

Sector

Technology

ML Signal

HOLD

Logo Esperion Therapeutics Inc.

ESPR

Esperion Therapeutics Inc.

HOLD

Current Price

$3.16

Market Cap

814.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SATL
ESPR
Founded
2010
2008
Country
United States
United States
Employees
154
N/A
Industry
Radio And Television Broadcasting And Communications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
679.0M
814.3M
IPO Year
N/A
2013

Fundamental Metrics

Financial Performance
Metric
SATL
ESPR
Price
$4.61
$3.16
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
4
Target Price
$5.50
$8.75
AVG Volume (30 Days)
8.7M
9.7M
Earning Date
05-12-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
60.71
EPS
N/A
N/A
Revenue
N/A
$403,135,000.00
Revenue This Year
$88.89
N/A
Revenue Next Year
$56.98
$12.81
P/E Ratio
N/A
N/A
Revenue Growth
N/A
21.31
52 Week Low
$1.26
$0.95
52 Week High
$12.00
$4.18

Technical Indicators

Market Signals
Indicator
SATL
ESPR
Relative Strength Index (RSI) 30.04 68.23
Support Level $3.08 $3.11
Resistance Level $5.93 $3.18
Average True Range (ATR) 0.69 0.02
MACD -0.27 -0.02
Stochastic Oscillator 5.65 75.00

Price Performance

Historical Comparison
SATL
ESPR

About SATL Satellogic Inc.

Satellogic Inc is a vertically integrated Earth observation company that designs, manufactures, and operates satellite systems, delivering decision-grade insights at scale to government and commercial customers. Through an end-to-end production and operations model, it provides governments with flexible options across their journey toward sovereign Earth observation. From access to high-frequency imagery and managed space systems to full satellite ownership, to supporting autonomous data availability and long-term technological independence. It has monitoring and alert-driven workflows that help defense and intelligence agencies, civil governments, and commercial operators transition from reactive tasking to proactive decision-making, providing mission-critical data when needed.

About ESPR Esperion Therapeutics Inc.

Esperion Therapeutics Inc is a commercial-stage biopharmaceutical company currently focused on bringing new medicines to patients that address unmet medical needs. It has developed and is commercializing U.S. Food and Drug Administration, or FDA, approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease (or CVD and are struggling with elevated low-density lipoprotein cholesterol, or LDL-C. The Company views its operations and manages its business in one operating segment, which is the business of researching, developing, and commercializing therapies for the treatment of patients with elevated LDL-C. The company depends almost entirely on the success of two products, the bempedoic acid tablet and the bempedoic acid/ezetimibe combination tablet.

Share on Social Networks: